复星医药(600196.SH)：控股子公司与纽科签订许可协议

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Nuco for the development of AR1001, a small molecule oral drug aimed at delaying the progression of Alzheimer's disease [1] Group 1: Company Information - Fosun Pharma's subsidiary, Fosun Pharma Industry, is the entity that entered into the licensing agreement with Nuco [1] - The drug AR1001 is characterized by its potent and highly selective inhibition of phosphodiesterase-5 (PDE-5) [1] Group 2: Product Details - AR1001 is intended for use in delaying the progression of Alzheimer's disease [1] - The drug is licensed from AriBio Co., Ltd., which is the upstream licensor for Nuco [1]